Core Viewpoint - Flexible Solutions International, Inc. reported its financial results for Q3 2025, highlighting a 13% increase in sales compared to the previous year, despite a net loss for the quarter due to increased costs and expenses related to new contracts and production preparations [6][2]. Financial Performance - Q3 2025 sales reached $10,556,291, up from $9,314,937 in Q3 2024, marking a 13% increase [6][8]. - The net loss for Q3 2025 was $503,358, or $0.04 per basic share, compared to a net income of $611,858, or $0.05 per basic share in Q3 2024 [6][8]. - Operating cash flow for the first nine months of 2025 was $4,257,973, or $0.34 per basic share, down from $5,909,621, or $0.47 per basic share in the same period of 2024 [6][8]. Operational Developments - The company has initiated full production for a second food-grade contract, which involved hiring and training four shifts of new employees [2]. - Significant improvements and equipment installations were completed in Panama, with final equipment installation and testing expected to occur before the end of the year [2][3]. - The NanoChem division and ENP subsidiary remain the primary sources of revenue and cash flow, with plans to begin production of existing products in Panama [3]. Future Outlook - The company anticipates substantial revenue generation from the food contract in Q4 2025, following the completion of improvements in Panama [2]. - Opportunities in various sectors, including detergent, water treatment, oil field extraction, and food and nutrition supplement manufacturing, are expected to drive future sales growth [3].

Core Insights - Oriental Culture Holding LTD. reported a significant decline in revenue for the first half of 2025, with total revenues of approximately $0.1 million, down 64% from approximately $0.4 million in the same period of 2024 [7][16] - The company faced operational challenges due to an investigation involving major shareholders, which negatively impacted customer confidence and trading activity on its platforms [5][15] - The company has made strategic changes, including the termination of its variable interest entity (VIE) structure, to adapt to its evolving business strategy [9] Financial Performance - Total revenues for the six months ended June 30, 2025, were approximately $0.1 million, compared to approximately $0.4 million for the same period in 2024, representing a decrease of approximately $0.3 million or 64% [7][19] - Gross profit decreased to approximately $0.1 million for the six months ended June 30, 2025, from approximately $0.3 million in 2024, with a gross margin of 84.7% compared to 65.8% in the prior year [7][32] - The net loss for the first half of 2025 was approximately $3.8 million, an increase of 104.2% from a net loss of approximately $1.9 million in the same period of 2024 [7][39] Revenue Breakdown - Listing service fees dropped significantly by approximately $0.1 million or 99.9%, from approximately $0.1 million in 2024 to approximately $100 in 2025, with no new collectibles or artwork successfully listed during the period [22][24] - Transaction fee revenue decreased by approximately $0.2 million or 71.9%, from approximately $0.2 million in 2024 to approximately $63,000 in 2025, attributed to a decline in total transaction value from approximately $86.8 million to approximately $61.5 million [26] - Marketing service fees fell to $0 in 2025 from approximately $66,000 in 2024, reflecting decreased demand for marketing services [29] Operational Changes - The company appointed Mr. Aimin Kong as COO and granted him 12 million preferred shares, valued at approximately $1.75 million [3] - The Board approved an increase in authorized share capital from $50,000 to $500,000, allowing for a significant increase in the number of ordinary shares [6][8] - The company has invested in a blockchain asset exchange system, costing $1.5 million, although the project has not yet launched [5] Investigation Impact - The investigation involving major shareholders has led to a substantial decrease in active customers, from 15,124 in the first half of 2024 to 4,504 in 2025 [15] - The investigation resulted in the freezing of bank accounts related to the company, which further impacted customer trust and operational capabilities [11][12] - The charges against the shareholders were withdrawn in May 2025, allowing for the unfreezing of bank accounts and resumption of normal operations [13]

Core Insights - Banzai International, Inc. reported significant financial growth in Q3 2025, with a gross profit of $2.3 million, representing a 213% increase from Q3 2024, and a gross margin expansion to 81.7%, an increase of 1,302 basis points [1][5][12]. Financial Performance - Revenue for Q3 2025 was $2.8 million, a 163% increase compared to Q3 2024 [5][10]. - Annual Recurring Revenue (ARR) reached $11.0 million for Q3 2025, marking a 168% year-over-year increase [5][10]. - The net loss for Q3 2025 was ($5.9) million, a significant reduction from a net loss of ($15.4) million in Q3 2024 [5][13]. - Adjusted EBITDA for Q3 2025 was ($2.2) million, compared to ($1.5) million in Q3 2024 [5][13]. Operational Highlights - The company expanded its customer base to over 140,000 as of November 14, 2025 [5]. - Banzai acquired the assets of Superblocks, an AI platform for creating SEO-optimized websites, enhancing its AI capabilities [5][7]. - The management team was strengthened with the appointment of Dean Ditto as CFO and Matt McCurdy as VP of Sales, both bringing extensive experience to drive growth [8]. Debt Management - Banzai executed a debt conversion agreement with senior debt holders, converting approximately $4.8 million of senior secured debt into equity, reflecting confidence in the company's strategy [4]. - The company paid off approximately $10.7 million of outstanding debt obligations year-to-date through August 31, 2025, and $32.7 million since September 2024 [4]. Strategic Initiatives - The company is focusing on driving self-service subscriber growth, expanding within enterprise and mid-market segments, and improving customer retention [9]. - Banzai is strategically investing in its software platform, sales and marketing, product innovation, and acquisition strategy while maintaining disciplined cost management [9].

Group 1 - The Company, Insight Digital Partners II, announced that holders of its initial public offering units may separately trade Class A ordinary shares and warrants starting November 18, 2025 [1] - The initial public offering consisted of 17,250,000 units, including 2,250,000 units from the underwriters' overallotment option, completed on October 30, 2025 [1] - Units not separated will continue to trade under the symbol "DYORU," while Class A ordinary shares and warrants will trade under "DYOR" and "DYORW," respectively [1] Group 2 - The Company is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination [4] - The Company aims to target high-growth sectors within the digital economy, including infrastructure for stablecoins and digital payments, staking and mining operations, trading platforms, and high-performance computing [4]

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Triumph (NYSE: TFIN) today announced that Aaron Graft, vice chairman and chief executive officer, will present at the Stephens Annual Investment Conference on Nov. 18, 2025 in Nashville, Tennessee. Triumph’s presentation is scheduled to begin at 3:00 p.m. CST. The presentation will be webcast live and may be accessed through this direct link, https://event.summitcast.com/view/4xGMMHuH7TkUARrFoGH3S3/XGQLV7F7Rzwh6eETnwhHQH or via the Company's website at ir.triumph.io ...

Expanded the Company’s compliance-driven logistics platform into the food sampling industryEntered agreement to install oral drug delivery equipment at Texas facility Established a subsidiary in India and advanced plans for a temperature-controlled pharmaceutical storage and distribution warehouseExtended the Company’s long-term contract with the City of Chicago through June 2026, including an increase in funding Upgraded Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring SP ...

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST) (“Strive” or the “Company”), the first Bitcoin treasury company amplified exclusively with perpetual preferred equity, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Consummated the reverse acquisition of Asset Entities Inc. and concurrently raised $762.6 million through PIPE financing transaction and warrant exercises through September 30, 2025, with the opportunity to ...

Core Insights - Verrica Pharmaceuticals Inc. reported significant progress in its commercial and clinical activities, particularly with its product YCANTH for molluscum contagiosum, and highlighted a strong foundation for future growth [2][4]. Financial Performance - The company reported $14.3 million in total revenue for Q3 2025, which includes $3.6 million from YCANTH and $10.7 million from license and collaboration revenue [4][21]. - For the nine months ending September 30, 2025, product revenue was $11.6 million, up from $6.3 million in the same period in 2024 [11][15]. - The net loss for Q3 2025 was $0.3 million, or $0.03 per share, compared to a net loss of $22.9 million, or $4.88 per share, for Q3 2024 [12][21]. Product and Pipeline Developments - YCANTH dispensed 37,642 applicator units in the first nine months of 2025, a 120% increase from 17,119 units in the prior year [2][11]. - The company initiated a global Phase 3 clinical program for YCANTH in common warts, with first patient enrollment expected in the U.S. by the end of 2025 [9][12]. - Positive feedback was received from the FDA regarding the study design for a Phase 3 program for VP-315, an oncology asset targeting basal cell carcinoma [4][12]. Regulatory Milestones - The approval of YCANTH for molluscum in Japan triggered a $10 million milestone payment to Verrica [12][15]. - The European Medicines Agency provided a pathway for YCANTH's registration in Europe without the need for additional Phase 3 studies [4][12]. Strategic Partnerships - Verrica's collaboration with Torii Pharmaceutical includes a 50/50 cost-sharing agreement for the global Phase 3 program, with Torii funding the first $40 million of trial costs [12][15]. - The company is exploring potential partnerships and non-dilutive financing discussions to support further development and commercialization of its late-stage programs [2][12].

Leuven, Belgium, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing solutions, today announced the results of the votes cast at its Extraordinary Shareholders’ Meeting, where all the proposed resolutions were approved. For additional information, please visit: https://investors.materialise.com/ About Materialise NV Materialise NV incorporates more than three decades of 3D printing experience into a range of ...

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT. A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will ...